Usual Adult Dose for Thyroid Cancer:
24 mg orally once a day
Comment:
-Treatment should be continued until disease progression or unacceptable toxicity.
Use: For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)
Usual Adult Dose for Renal Cell Carcinoma:
18 mg orally once a day
Comments:
-This drug is given in combination with 5 mg everolimus.
-Refer to everolimus prescribing information for recommended dosing information.
-Treatment should be continued until disease progression or unacceptable toxicity.
Use: In combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy
Usual Adult Dose for Hepatocellular Carcinoma:
-Weight less than 60 kg: 8 mg orally once a day
-Weight 60 kg or greater: 12 mg orally once a day
Comment:
-Treatment should be continued until disease progression or unacceptable toxicity.
Use: For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
Usual Adult Dose for Endometrial Carcinoma:
20 mg orally once daily
Comments:
-This drug is given in combination with pembrolizumab 200 mg IV over 30 minutes every 3 weeks.
-Refer to the pembrolizumab prescribing information for other dosing information.
-Treatment should be continued until disease progression or unacceptable toxicity.
Use: In combination with pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation
 Detailed Lenvatinib dosage information
